Surgery Partners (SGRY) Form 144 — 5,627 Shares Proposed Sale; Prior Insider Sales Listed
Rhea-AI Filing Summary
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 5,627 common shares through UBS Financial Services on September 26, 2025. The shares were recorded as acquired the same day via equity compensation and an equity option exercise. The reported aggregate market value for the proposed sale is $123,794 and the issuer has 128,209,410 shares outstanding. The filing also lists multiple recent open-market sales by Wayne DeVeydt totaling 713,977 shares sold across dates from August 21, 2025 through September 23, 2025 with individual gross proceeds reported for each lot.
Positive
- Form 144 was filed and contains required details including broker, share counts, acquisition method, and aggregate market value
- Proposed sale size is small relative to outstanding shares (5,627 vs 128,209,410 outstanding)
Negative
- Significant insider selling disclosed: Wayne DeVeydt sold 713,977 shares across multiple dates in the past three months
- Immediate exercise-and-sale: the 5,627 shares were acquired and marked for sale on the same date (09/26/2025), indicating an immediate disposition
Insights
TL;DR: Insider exercised options and filed a timely Form 144 to sell 5,627 shares; sizable prior sales by a second insider were disclosed.
The Form 144 documents a proposed brokered sale of 5,627 common shares acquired by equity compensation and an option exercise on the same date, indicating a near-term disposition. The filing includes explicit market value ($123,794) and the company share count (128,209,410), allowing calculation of the sale's relative size (very small fraction of outstanding shares). Separately, the filing lists detailed historic sales by Wayne DeVeydt totaling 713,977 shares with individual gross proceeds for each transaction. From a trading-disclosure perspective the filing is complete and allows investors to verify timing and proceeds; it does not include any forward-looking or operational data.
TL;DR: Multiple reported insider dispositions may be material to shareholders' perception but the Form 144 itself is a routine required disclosure.
The document shows an insider exercise-and-sale of 5,627 shares and extensive recent sales by another person, Wayne DeVeydt, amounting to 713,977 shares. These entries are factual disclosures required under Rule 144 and the filer certifies no undisclosed material adverse information. The filing provides identity of broker, transaction dates, and gross proceeds for past sales, which supports transparency on insider liquidity events. The filing does not provide reasons for the sales or link them to company performance.